931 Shares in Natera, Inc. (NASDAQ:NTRA) Acquired by Arcadia Investment Management Corp MI

Arcadia Investment Management Corp MI acquired a new position in Natera, Inc. (NASDAQ:NTRA) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 931 shares of the medical research company’s stock, valued at approximately $147,000.

Other institutional investors also recently modified their holdings of the company. Chartwell Investment Partners LLC increased its position in shares of Natera by 37.9% in the third quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock worth $5,243,000 after purchasing an additional 11,362 shares during the last quarter. Cerity Partners LLC increased its position in shares of Natera by 27.0% in the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock worth $10,936,000 after purchasing an additional 18,316 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Natera in the third quarter worth approximately $385,000. Everence Capital Management Inc. bought a new position in shares of Natera in the fourth quarter worth approximately $573,000. Finally, First Turn Management LLC bought a new position in Natera during the third quarter valued at approximately $19,760,000. 99.90% of the stock is currently owned by institutional investors.

Natera Trading Down 2.6 %

Shares of NTRA stock opened at $168.19 on Friday. The stock has a fifty day moving average of $168.06 and a 200 day moving average of $144.78. Natera, Inc. has a 52 week low of $69.14 and a 52 week high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. Barclays assumed coverage on shares of Natera in a research report on Thursday, January 23rd. They set an “overweight” rating and a $200.00 price target on the stock. Canaccord Genuity Group increased their price target on shares of Natera from $165.00 to $180.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. Robert W. Baird increased their price target on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Finally, JPMorgan Chase & Co. raised their target price on shares of Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and an average price target of $170.94.

Insider Buying and Selling at Natera

In other Natera news, insider John Fesko sold 669 shares of the firm’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $159.60, for a total transaction of $106,772.40. Following the completion of the transaction, the insider now owns 114,142 shares of the company’s stock, valued at approximately $18,217,063.20. This trade represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Steven Leonard Chapman sold 78,553 shares of the firm’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $12,958,888.41. Following the transaction, the chief executive officer now directly owns 267,629 shares of the company’s stock, valued at $44,150,756.13. This represents a 22.69 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 295,772 shares of company stock valued at $49,741,699. 7.60% of the stock is currently owned by company insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.